Compare Alpha-1 tests

Most commercial labs and several specialized Alpha-1 laboratories perform the tests to identify Alpha-1.

Three blood tests can be used to diagnose and identify the specific genetic type of Alpha-1.

Alpha1-Antitrypsin (AAT) blood level:

Tests for the amount of the AAT protein in your blood. Often is the first test ordered, but does not provide any genetic information.


Identifies whether the genes you have to make AAT are normal or abnormal.


Identifies exactly which AAT protein your body makes. There are several different AAT proteins your body could make, depending on your genetic makeup. Some of the proteins are normal and some are abnormal, which can result in low levels of AAT in your blood.


Up to 25 million Americans are estimated to carry an abnormal Alpha-1 gene1

Many of the estimated 25 million carriers for Alpha-1 have an increased risk of lung disease.1,2 Talk to your doctor about the free Grifols AlphaKit.

PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to the risk of severe hypersensitivity and in patients with a history of anaphylaxis or other severe systemic reactions to alpha1-PI.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. Should hypersensitivity symptoms be observed, promptly stop infusion and begin appropriate therapy. Have epinephrine and other appropriate therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

The most common drug-related adverse reaction observed at a rate of >5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

Please click here for full Prescribing Information for PROLASTIN-C.


  1. de Serres FJ, Blanco I, Fernández-Bustillo E. Genetic epidemiology of Alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003:64(5):382-397.
  2. Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008;168(10):1097-1103.
  3. Alpha-1 Coded Testing (ACT) Study. Confidential Testing for Alpha-1 Antitrypsin Deficiency. Alpha-1 Foundation. Version 1.1, May 2007.
  4. Grifols AlphaKit Insert. Item # PR76-0608. Grifols
  5. Testing for Alpha-1. AlphaTest® page. Accessed December 2, 2009.
  6. AlphaTest® Kit Mailer. Alpha1Center, 1000 E. 100 South, Suite 109, Salt Lake City, UT 84102.